Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma

Head and Neck

Volumn 32, Issue 7, 2010, Pages 877-885

  Lee, Jeng Woei ^a   Hsiao, Wei Ting ^a   Lee, Kuei Fang ^a   Sheu, Lai Fa ^b   Hsu, Hsue Yin ^a   Hsu, Lee Ping ^c   Su, Borcherng ^c   Lee, Moon Sing ^c   Hsu, Yih Chih ^d   Chang, Chung Hsing ^e  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Head and neck cancers; Immunohistochemistry; Nasopharyngeal carcinoma; Par 4

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CANCER; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CANCER; NASOPHARYNX CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROSTATE APOPTOSIS RESPONSE 4 GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KI-67 ANTIGEN; MALE; MOUTH NEOPLASMS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77954415255     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21282     Document Type: Article

References (35)

1. Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev 1993;15:466-485.
2. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1-9.
3. Wu LS-H. Construction of evolutionary tree models for nasopharyngeal carcinoma using comparative genomic hybridization data. Cancer Genet Cytogenet 2006;168:105-108.
4. Johnstone RW, Tommerup N, Hansen C, Vissing H, Shi Y. Mapping of the human PAWR (par-4) gene to chromosome 12q21. Genomics 1998;53:241-243. (Pubitemid 28496616)
5. Sells SF, Wood DP Jr, Joshi-Barve SS, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994;5:457-466.
6. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-1161.
7. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by Akt is essential for cancer cell survival. Mol Cell 2005;20:33-44.
8. Diaz-Meco MT, Municio MM, Frutos S, et al. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996;86:777-786.
9. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-6956.
10. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-7263. (Pubitemid 32946523)
11. Mundle SD. Par-4: a common facilitator/enhancer of extrinsic and intrinsic pathways of apoptosis. Leuk Res 2006;30:515-517.
12. Pruitt K, Ülkü AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-23370.
13. Qiu SG, Krishnan S, el-Guendy N, Rangnekar VM. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 1999;18:7115-7123.
14. Nalca A, Qiu SG, el-Guendy N, Krishnan S, Rangnekar VM. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999;274:29976-29983.
15. Barradas M, Monjas A, Diaz-Meco MT, Serrano M, Moscat J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J 1999;18:6362-6369.
16. Garcia-Cao I, Duran A, Collado M, et al. Tumor-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6:577-583.
17. Butler J, Rangnekar VM. Par-4 for molecular therapy of prostate cancer. Curr Drug Targets 2003;4:223-230.
18. Lee JW, Lee KF, Hsu HY, et al. Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. Cancer Lett 2007;257:252-262.
19. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003;278:19995-20005.
20. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999;18:623-631.
21. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:451-462.
22. Boehrer S, Chow KU, Beske F, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002;62:1768-1775.
23. Verma YK, Gangenahalli GU, Singh VK, et al. Cell death regulation by B-cell lymphoma protein. Apoptosis 2006;11:459-471.
24. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003;23:5516-5525.
25. Affar El B, Luke MP, Gay F, et al. Targeted ablation of Par-4 reveals a cell type-specific susceptibility to apoptosis-inducing agents. Cancer Res 2006;66:3456-3462.
26. Lee JW, Liu PF, Hsu LP, Chen PR, Chang CH, Shih WL. EBV LMP-1 negatively regulates expression and proapoptotic activity of Par-4 in nasopharyngeal carcinoma cells. Cancer Lett 2009;279:193-201.
27. Goswami A, Ranganathan P, Rangnekar VM. The phosphinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 2006;66:2889-2892.
28. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007;67:1927-1934. (Pubitemid 46424208)
29. Cook J, Krishnan S, Ananth S, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999;18:1205-1208.
30. Boehrer S, Chow KU, Puccetti E, et al. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2001;2:103-107.
31. Bartkova J, Hořejší Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870. (Pubitemid 40558993)
32. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913. (Pubitemid 40559004)
33. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002;2:221-225.
34. Lowe SW, Cepero E, Evan G. Intrinsic tumor suppression. Nature 2004;432:307-315.
35. Spurgers KB, Chari NS, Bohnenstiehl NL, McDonnell TJ. Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy. Cell Death Differ 2006;13:1360-1370.